US SEC Trading Suspension Halt Orders — September 04, 2026

04-09-2026

Nixxy, Inc. received a Nasdaq deficiency notice on September 1, 2026, for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, triggering a 180-day grace period to regain compliance. Concurrently, the company announced the resignation of director Ashissh Raichura and the appointment of Joe Conlon as a new director and Audit Committee Chairman, while Elsa Sung was appointed CFO with an annual base salary of $169,800 and equity awards. The delisting risk and leadership changes create significant uncertainty, though the company intends to monitor its bid price and explore options to cure the deficiency.

• · Nasdaq notice does not result in immediate delisting; company has 180-day grace period ending around February 28, 2027.
• · If not compliant by then, company may qualify for a second 180-day period if it meets other listing standards and intends to effect a reverse stock split.
• · Ashissh Raichura's resignation was not due to any disagreement with the company.
• · Elsa Sung has over 20 years of financial experience, is a licensed CPA (inactive), and previously served as CFO of a Nasdaq-listed company.
• · Joe Conlon received 50,000 shares upfront and 50,000 shares annually vesting quarterly, plus $3,000 monthly.
• · CFO employment agreement includes one month severance if terminated without cause after 90 days, and four months severance upon change of control termination.

04-09-2026

Arcadia Biosciences, Inc. (RKDA) received a Nasdaq deficiency letter on August 31, 2026, for failing to meet the minimum $2,500,000 stockholders' equity requirement, reporting only $633,000 as of June 30, 2026. The company also does not meet the alternatives of market value of listed securities or net income from continuing operations. While the stock continues trading for now, Arcadia has until October 15, 2026, to submit a compliance plan, with no assurance of acceptance or successful regaining of compliance.

• · The company has 45 calendar days (until October 15, 2026) to submit a compliance plan to Nasdaq.
• · If Nasdaq accepts the plan, an extension of up to 180 calendar days from the date of the letter may be granted.
• · If the plan is not accepted, the company can appeal to a Nasdaq Hearings Panel, which would ordinarily stay any suspension or delisting pending a written decision.
• · The company also does not meet the alternative compliance standards of market value of listed securities or net income from continuing operations.

04-09-2026

Archer Aviation Inc. filed an 8-K reminding holders that its public warrants (ACHR WS) will expire on September 16, 2026, at 5:00 p.m. New York City time. Trading of the warrants was halted by the NYSE on September 1, 2026, and will remain halted until trading is suspended before the open on September 15, 2026. Any unexercised warrants after the expiration date will become void with no further rights; the company's Class A common stock (ACHR) continues to trade normally on the NYSE.

• · The warrant expiration date is September 16, 2026, at 5:00 p.m. New York City time.
• · Warrant trading was halted on September 1, 2026, under NYSE Section 802.01D, and will remain halted until trading is suspended before the open on September 15, 2026.
• · The company's Class A common stock continues to trade on the NYSE under the symbol ACHR.
• · The warrant agreement was originally dated October 27, 2020, between Atlas Crest Investment Corp. and Continental Stock Transfer & Trust Company.

04-09-2026

SCWorx Corp. received a Nasdaq Staff letter on September 2, 2026, notifying it that it fails the minimum publicly held shares requirement (only 89,782 shares vs. 500,000 required). This adds to existing deficiencies in the minimum bid price and market value of publicly held shares requirements. The company intends to respond to the Nasdaq Hearings Panel by September 9, 2026, but faces significant risk of delisting.

• · The company had only 89,782 publicly held shares as of September 1, 2026, far below the 500,000 minimum.
• · The company also remains deficient in the minimum bid price requirement ($1.00) and the market value of publicly held shares requirement ($1,000,000).
• · A 1-for-12 reverse stock split effective August 3, 2026, reduced publicly held shares below the threshold.
• · The company must submit its views to the Nasdaq Hearings Panel by September 9, 2026.
• · Regaining compliance with the publicly held shares requirement will likely require issuing additional common stock, causing dilution.
• · If delisted, the stock would trade over-the-counter, reducing liquidity and price transparency.

04-09-2026

Matinas BioPharma received a third NYSE American noncompliance notice on August 31, 2026, for failing to meet the $2.0 million stockholders' equity continued listing standard (Section 1003(a)(i)), with reported equity of $1.8 million as of June 30, 2026. The company is already under a plan period through October 2, 2027, to regain compliance with all equity standards, and the stock remains listed and trading under 'MTNB' with a .BC indicator. While the notice has no immediate impact on trading, the company faces escalating delisting risk if it fails to meet the equity thresholds by the deadline.

• · The company has reported losses from continuing operations and/or net losses in its five most recent fiscal years.
• · Previous noncompliance notices were received on April 3, 2026 (Section 1003(a)(ii)) and June 26, 2026 (Section 1003(a)(iii)).
• · The NYSE American accepted the company's plan and granted a plan period through October 2, 2027.
• · If compliance is not achieved by the plan period deadline, delisting proceedings may be initiated.
• · The .BC indicator will be disseminated with the ticker symbol until compliance is regained.

04-09-2026

Quince Therapeutics received a Nasdaq notice on August 31, 2026, for failing to meet the minimum stockholders' equity requirement of $10,000,000, as its equity was ($35,324,000) as of June 30, 2026. The company has until October 15, 2026, to submit a compliance plan, with a possible extension to February 27, 2027. While the stock remains listed and trading under 'QNCX', the company is exploring alternatives, including a proposed name change to 'IRulya Therapeutics Inc.' and a transfer to the Nasdaq Capital Market under 'IRLA', but there is no assurance of regaining compliance.

• · The company has a negative stockholders' equity of ($35,324,000), which is $45.324 million below the required $10 million minimum.
• · The company filed a definitive proxy statement (DEF14A) on August 25, 2026, related to the proposed name change and transfer to the Nasdaq Capital Market.
• · If the plan is not accepted, the company retains the right to appeal, and the stock would remain listed until the appeal process concludes.
• · The company is evaluating various alternative courses of action to regain compliance, but there is no assurance of success.